Press Releases

Medtronic plc, a global leader in healthcare technology, today announced that the Stealth AXiS™ surgical system and the Corsano™* multi-parameter wearable have been named to the TIME Best Inventions of 2026 list. The annual award highlights the most impactful new products and ideas of the year, assessed by TIME editors. The dual recognition highlights the Medtronic enterprise-wide commitment to transforming healthcare through connected technologies that help clinicians m

Welldoc®, a leader in AI-powered health technology for complex conditions, today launched its next-generation platform: a digital-first care loop connecting an individual’s daily health experience directly to their care team. Unlike consumer chatbots, the care loop runs on Welldoc’s clinically validated Small Language Models (SLMs), ensuring guidance is personalized, measurable, and connected to a clinician. At its center is Simon, Welldoc’s AI care agent, orchestrating

KARL STORZ, a global leader in advanced surgical visualization and integrated operating room solutions, today announced that the U.S. Food and Drug Administration (FDA) has cleared expanded indications for the TIPCAM1™ Rubina™ video endoscope for use in selected cardiac surgical procedures. TIPCAM1™ Rubina™ combines 4K visualization, stereoscopic 3D imaging, and near-infrared fluorescence imaging (NIR/ICG) in a single video endoscope, helping surgeons visuali

Blink Anesthesia announced today that two additional academic integrated delivery networks (IDNs) in the Midwest have standardized the TwitchView® Train of Four (TOF) Monitor across their surgical departments. One health system has completed its system-wide deployment, and the second is on track to complete its rollout by the end of the year. By standardizing TwitchView®, both systems aim to establish a consistent, quantitative approach to neuromuscular blockade management,

Radformation, a leading provider of intelligent automation solutions for radiation oncology, today announced the expanded U.S. Food and Drug Administration (FDA) 510(k) clearance (K261718) for EZFluence to include OptiPlan*, its new automated VMAT planning module. The clearance makes OptiPlan available for clinical use in the United States, expanding access following its introduction in Europe and Canada. “OptiPlan was built in direct response to what we were hearing from our

Epitel, Inc. today announced that its REMI™ Neuro Monitoring Home Health Hub has been selected by the U.S. Food and Drug Administration (FDA) to participate in the Reducing Readmissions through Device Innovation for the Home (READI-Home) Innovation Challenge. Epitel is one of the first two companies selected to advance to the program’s interaction phase. About the FDA READI-Home Innovation Challenge: Launched as part of the FDA Center for Devices and Rad

Ernest Health, a national owner and operator of freestanding inpatient rehabilitation hospitals, today announced Phase 1 of its North Carolina development program: six freestanding inpatient rehabilitation hospitals in Winston-Salem, Mooresville, Gastonia, Hickory, South Asheville/Arden and Goldsboro. Sites have been secured in all six markets and are under the control of the program's development partner. The hospitals are being developed in partnership with Summit Healthcare G

Bayer today announced that the U.S. Food and Drug Administration (FDA) approved KERENDIA® (finerenone) to reduce urinary albumin-to-creatinine ratio (UACR), which is expected to reduce the risk of sustained estimated glomerular filtration rate (eGFR) decline and end-stage kidney disease in adults with chronic kidney disease (CKD) associated with type 1 diabetes (T1D), following the agency’s Priority Review of the supplemental New Drug Application (sNDA).1 Key Facts

Adagio Medical Holdings, Inc. (Nasdaq: ADGM) (“Adagio” or “the Company”), a leading innovator in catheter ablation technologies for the treatment of cardiac arrhythmias, today announced highlights from the first patient enrolled in the Company’s study evaluating its next-generation vCLAS™ Ultra Ultra-Low Temperature Ablation (“ULTA”) Ventricular Ablation System. The study is designed to support a Premarket Approval (“PMA”) supplement

ZBeats Inc. today announced it has received U.S. Food and Drug Administration (FDA) 510(k) clearance (K261580) for its ZBPro Diagnostic v2.0 software. This clearance expands ZBeats' independent ECG analysis platform to support recordings from one minute up to 14 days, including Holter configurations and wearable patches. The ZBeats team will showcase the newly cleared version this week at HRX Live 2026 in Atlanta, Georgia. Experience ZBPro v2.0 at HRX 2026